The development of new BCG Immunotherapy against bladder cancer with immune checkpoint inhibitor
| Project/Area Number |
17K11147
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 膀胱癌 / BCG / PD-1経路阻害薬 / 免疫チェックポイント阻害薬 / 免疫チェックポイント阻害剤 / BCG治療 |
|---|
| Outline of Final Research Achievements |
We have examined the antitumor effect of the combined therapy of BCG and immune checkpoint inhibitor in a mouse local bladder cancer model. We could get the result that the combination therapy had a stronger antitumor effect than BCG monotherapy. Although, we analyzed various method to confirm the mechanism of the combination therapy. As a result, I could not find the evidence that the acquired immunocytes such as cytotoxic CD8 + T cells (CTL) was responsibility. The further research is needed to find out the reason for this.
|
| Academic Significance and Societal Importance of the Research Achievements |
筋層非浸潤性膀胱癌は、初期治療として経尿道的膀胱腫瘍切除術（TURBT）が行われている。TURBTにより、筋層非浸潤性膀胱癌の治療は著しく改善されてきたが、TURBTだけでは膀胱内再発・進展を完全に防止することはできず、TURBT施行後の再発防止目的で、BCGの膀胱内注入療法（BCG療法）が行われている。今回の知見によりPD-1経路阻害薬をBCG上乗せすることで抗腫瘍効果の相乗効果が見られたことは、現状において選択肢の少ない今後の膀胱癌治療の福音となることが予想される。
|
Report
(4 results)
Research Products
(1 results)
